The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

A Phase 1B, Repeated Dose Study, to Evaluate the Safety, PD and PK Profile of CM-101 in NAFLD Patients With Normal Liver Function Tests and Stable NAFLD/NASH Patients With NAFLD Activity Score (NAS) < 3-The SPARK Study

A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions to be treated with CM-101.

Study Overview

• Status: Completed
• Conditions: Nonalcoholic Fatty Liver Disease
• Intervention / Treatment: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Placebo - Study Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part Two

Detailed Description

This study is designed to assess the safety and preliminary pharmacodynamics of repeated administrations of CM-101 in two subject populations. The objective of part one of this study is to demonstrate that repeated treatment with CM-101 will be safe and well tolerated in NAFLD subjects that have normal liver functions and are in general good health. A second expansion part will be carried out that will include patients with NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• Israel
  • Jerusalem, Israel, 91120
    • Hadassah University Hospital - Ein Kerem

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients with US confirmation of NAFLD without evidence of NASH;
2. Patients with normal liver function tests (i.e. ALT, AST and ALP).
3. Patients in general good health expected for the preceding 6 months;
4. Women of childbearing potential must agree to use an approved form of contraception prior to study entry and for the duration of study participation through 60 days after the last dose of the study medication. Confirmation that female patients are not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for postmenopausal or surgically sterilized women;
5. Male patients must agree to use a barrier method of contraception or abstinence for the duration of study participation through 60 days after the last dose of the study medication;
6. Patient must be able to read, understand, and sign the informed consent forms (ICF), communicate with the investigator, and understand and comply with protocol requirements

Exclusion Criteria:

1. Patients with medical/surgical history of gastric bypass surgery, orthotopic liver transplant (OLT) or patients that are planned for such interventions;
2. Documented history of chronic liver disease (e.g., autoimmune hepatitis (>1:160 ANA with histologic features), Wilson's disease, Hemochromatosis (Ferritin >500 ug/L and percent iron saturation >45%), Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Alcoholic Liver Disease);

3. Presence of chronic viral hepatitis:

   • Chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg) positive);
   • Chronic hepatitis C virus (HCV) infection (HCV Ab and HCV ribonucleic acid (HCV RNA) positive).

   Patients cured of HCV infection less than 5 years prior to the Screening visit are not eligible;

4. History of or current diagnosis of HCC;
5. Known human immunodeficiency virus (HIV) infection (HIV Ab and HIV ribonucleic acid (HIV RNA) positive);
6. Patients with diabetes mellitus type 1;
7. Patients with uncontrolled diabetes mellitus type 2, i.e. HbA1c ≥ 9% (75 mmol/mol) at the time of screening or patients that are treated with insulin;
8. Patients treated with chronic medication including but not limited to anti-retrovirals, tamoxifen, methotrexate, cyclophosphamide, isotretinoin, bile acid binding resins, or pharmacologic doses of oral glucocorticoids (≥10 mg of prednisone per day or equivalent) within the 12 weeks of screening;

9. Patients treated with the below listed medications can be enrolled into the study if these medications are deemed medically necessary, cannot be stopped and the investigator anticipates their dose will remain stable during the study:

   1. Stable doses of anti-diabetic medications (e.g. metformin, sulfonylureas, SGLT2 inhibitors, glitazones (thiazolidinediones), dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 analogs) for at least 6 months prior to screening.
   2. Stable doses of ACE inhibitors, angiotensin II receptor antagonists, beta-blockers and thiazide diuretics for at least 6 months prior to screening.
   3. Stable doses of fibrates, statins, niacin, ezetimibe for at least 6 months prior to screening.
   4. Stable doses of vitamin E for at least 6 months prior to screening.
   5. Replacement therapy (e.g., thyroxine, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed as long as the treatment is stable forat least 6 months prior to screening. For further clarification Insulin treatment is not allowed.

10. Patients with the following medical conditions:

    • Cardiovascular conditions:

      1. Unstable angina (clinical definition)
      2. History of myocardial infarction, cardiac catheterization (for any reason) or coronary artery bypass graft within 18 months of screening
      3. Atrial fibrillation
      4. Congestive Heart failure (clinical definition) or hypertrophic cardiomyopathy
      5. Heart valve disorder (i.e., prosthetic valve or known hemodynamically relevant valve disease)
      6. Unstable angina
    • Uncontrolled thyroid disease
    • Portal hypertension
    • CNS disturbance such as history of Stroke (CVA and/or TIA), Parkinson's disease, Alzheimer's disease, or history of seizure disorders.
    • Autoimmune disease that has required systemic treatment in the 2 years preceding study screening (i.e., with the use of disease-modifying agents, corticosteroids or immunosuppressive drugs).
    • Clinically significant renal dysfunction defined as a serum creatinine concentration >1.4 mg/dL (females) or >1.6 mg/dL (males) and/or a blood urea nitrogen (BUN) concentration >45 mg/dL at screening.
    • Patients diagnosed or treated for any malignancy within 5 years of screening, except in situ malignancy, or low-risk prostate, skin (basal or squamous cell cancer or other localized non-melanoma) or cervix cancer after curative therapy.
    • Any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the patient or impair the assessment of study results.
    • Presence of any condition that could, in the opinion of the investigator, compromise the patient's ability to participate in the study, including a history of substance abuse or a psychiatric condition requiring hospitalization or emergency room visit within 2 years of Screening;

11. Patients with the following blood test abnormalities:

    • Abnormal coagulation tests: INR,
    • Total bilirubin (TB) ≥2 ULN,
    • Serum Albumin < 3.4 g/dL,
    • Platelet count <130 × 10^9/L;
12. History of or current significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening (significant alcohol consumption is defined as more than 20 g/day in females and more than 30 g/day in males, on average);
13. Patients with history of substance abuse (including alcohol abuse as defined above) in the past or a positive screen for drugs of abuse (opioids and cannabinoids) or alcohol at screening;
14. Female patients who are pregnant or nursing, or male/female patients who are planning a pregnancy during the course of the study;
15. Patients that are unavailable for follow-up assessments or any concern the investigator may have for patient's compliance with the protocol procedures;
16. Patients that are currently participating or have participated in an interventional clinical study within 3 months prior to screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Anti-human CCL24 monoclonal antibody (CM-101) - study Part One; Anti-human CCL24 monoclonal antibody (CM-101) NAFLD subjects that have normal liver functions - (Cohort 1: 2.5 mg/kg intravenously and Cohort 2: 5.0 mg/kg subcutaneously)	Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Placebo Comparator: Placebo - Study Part One; Placebo Comparator	Drug: Placebo - Study Part One; Placebo Comparator
Experimental: Anti-human CCL24 monoclonal antibody (CM-101) - Study Part Two; Anti-human CCL24 monoclonal antibody (CM-101) NAFLD/NASH patients with NAS < 3 that are in general good health and have normal liver functions - 2.5 mg/kg intravenous infusion	Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Placebo Comparator: Placebo - Study Part Two; Placebo Comparator	Drug: Placebo - Study Part Two; Placebo Comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and characteristics of adverse events (AEs) occurring following multiple doses	Incidence and characteristics of adverse events (AEs) occurring following multiple doses	Up to 18 weeks
Evaluation of the development of anti-drug antibodies (ADA) - Study Part 1	Evaluation of the development of anti-drug antibodies (ADA) following repeated administrations of CM-101 -	Up to 18 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Maximum CM-101 plasma concentration (Cmax) - Study Part 1	Plasma PK parameters of CM-101 - Maximum CM-101 plasma concentration (Cmax)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 - Time to Cmax (tmax) - Study Part 1	Plasma PK parameters of CM-101 following multiple administrations - Time to Cmax (tmax)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf - Study Part 1	Plasma PK parameters of CM-101 following multiple administrations - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Terminal elimination rate constant (λz) - Study Part 1	Plasma PK parameters of CM-101 - Terminal elimination rate constant (λz)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Terminal elimination half-life (T½) - Study Part 1	Plasma PK parameters of CM-101 - Terminal elimination half-life (T½)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Maximum CM-101 plasma concentration (Cmax) - Study Part 2	Plasma PK parameters of CM-101 - Maximum CM-101 plasma concentration (Cmax)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Time to Cmax (tmax) - Study Part 2	Plasma PK parameters of CM-101 - Time to Cmax (tmax)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf - Study Part 2	Plasma PK parameters of CM-101 - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 - Terminal elimination rate constant (λz) - Study Part 2	Plasma PK parameters of CM-101 following multiple administrations - Terminal elimination rate constant (λz)	Up to 18 weeks
Plasma Pharmacokinetics (PK) parameters of CM-101 - Terminal elimination half-life (T½) - Study Part 2	Plasma PK parameters of CM-101 following multiple administrations - Terminal elimination half-life (T½)	Up to 18 weeks
Evaluation of the development of anti-drug antibodies (ADA) following repeated administrations of CM-101 - Study Part 2	Evaluation of the development of anti-drug antibodies (ADA) of CM-101	Up to 18 weeks
Liver function test: ALT (alanine aminotransferase) - Study Part 2 Only	Percentage and absolute change from baseline in liver enzymes (liver function test) in multiple timepoints - ALT (alanine aminotransferase)	Over a treatment period of 18 weeks
Liver function test: AST (Aspartate Aminotransferase) - Study Part 2 Only	Percentage and absolute change from baseline in liver enzymes (liver function test) in multiple timepoints - Liver function test: AST (Aspartate Aminotransferase)	Over a treatment period of 18 weeks
Liver function test: GGT (gamma-glutamyltransferase) - Study Part 2 Only	Percentage and absolute change from baseline in liver enzymes (liver function test) in multiple timepoints - Liver function test: GGT (gamma-glutamyltransferase)	Over a treatment period of 18 weeks
Liver function test: ALP (Alkaline Phosphatase) - Study Part 2 Only	Percentage and absolute change from baseline in liver enzymes (liver function test) in multiple timepoints - Liver function test:ALP (Alkaline Phosphatase)	Over a treatment period of 18 weeks
Change from baseline to end of treatment in: fibrosis-4 (FIB-4) score - Study Part 2 Only	Change from baseline to end of treatment in: fibrosis-4 (FIB-4) score	Up to 15 Weeks
Change from baseline to end of treatment in: Aspartate transaminase (AST) ratio - Study Part 2 Only	Change from baseline to end of treatment in: AST ratio	Up to 15 Weeks
Change from baseline to end of treatment in: Alanine aminotransferase (ALT) ratio - Study Part 2 Only	Change from baseline to end of treatment in: ALT ratio	Up to 15 Weeks
Change from baseline to end of treatment in: APRI (AST to platelet ratio index) - Study Part 2 Only	Change from baseline to end of treatment in: APRI (AST to platelet ratio index)	Up to 15 Weeks
Change from baseline to end of treatment in: Nonalcoholic fatty liver disease (NAFLD) Fibrosis Score - Study Part 2 Only	Change from baseline to end of treatment in: NAFLD Fibrosis Score	Up to 15 Weeks

Collaborators and Investigators

• Sponsor: ChemomAb Ltd.
• Investigators: Study Chair: Arnon Aharon, MD, ChemomAb Ltd.; Principal Investigator: Rifaat Safadi, MD, Hadassah University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 11, 2018
• Primary Completion (Actual): April 27, 2020
• Study Completion (Actual): April 27, 2020

Study Registration Dates

• First Submitted: August 30, 2023
• First Submitted That Met QC Criteria: September 13, 2023
• First Posted (Actual): September 21, 2023

Study Record Updates

• Last Update Posted (Actual): September 21, 2023
• Last Update Submitted That Met QC Criteria: September 13, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antibodies; Immunoglobulins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Streptococcal polysaccharide type III group B
• Other Study ID Numbers: CM-101-I-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No